688163.SHG Shanghai Serum Bio-Technology Co. Ltd. A
- Market cap
- CNY 3.32B
- P/E
- 62.6x
- P/B
- 2.78x
- ROE
- 7.4%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688163.SHG undervalued?
Graham number688163.SHG trades 178.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Serum Bio-Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Serum Bio-Technology Co. Ltd. A yet.
Shanghai Serum Bio-Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Serum Bio-Technology Co. Ltd. A
Shanghai Serum Bio-Technology Co., Ltd. engages in research, development, production, operation, and sales of antitoxin and antivenom serum products for biotoxins and biosafety in China. It offers equine anti-tetanus immunoglobulin, antivenom, and anti-rabies serum products. The company also engaged in the collection and sale of animal immune plasma. The company was founded in 1999 and is based in Shanghai, China.
Full company profileShanghai Serum Bio-Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Serum Bio-Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 188M | 186M | 209M | 174M | 190M | 195M | 196M | 231M |
| Gross Profit | 162M | 155M | 175M | 146M | 144M | 152M | 153M | 181M |
| Operating Income | 85.4M | 84.1M | 91.2M | 60.6M | 38.0M | 53.4M | 54.9M | 92.1M |
| EBITDA | 96.1M | 97.9M | 104M | 89.6M | 63.2M | 71.1M | 83.7M | 95.8M |
| Net Income | 65.8M | 63.2M | 76.5M | 64.2M | 38.8M | 44.3M | 51.8M | 84.1M |
| EPS | 0.81 | 0.78 | 0.94 | 0.59 | 0.36 | 0.41 | 0.48 | 0.78 |
| Balance Sheet | ||||||||
| Total Assets | 365M | 326M | 403M | 1.17B | 1.13B | 1.12B | 1.16B | 1.19B |
| Total Liabilities | 28.2M | 33.1M | 33.3M | 44.9M | 42.6M | 24.5M | 44.6M | 57.5M |
| Shareholders' Equity | 337M | 293M | 370M | 1.12B | 1.09B | 1.10B | 1.11B | 1.13B |
| Cash & Short-term Investments | 132M | 118M | 116M | 516M | 151M | 182M | 33.3M | 79.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | 81.9M | 98.4M | 92.3M | 67.9M | 32.8M | 50.3M | 60.5M | - |
| Capital Expenditure | 25.1M | 17.9M | 27.6M | 26.5M | 28.7M | 59.4M | 59.6M | 105M |
| Free Cash Flow | 56.7M | 80.4M | 64.7M | 41.5M | 4.15M | -9.12M | 925K | -53.2M |
| Ratios | ||||||||
| ROE | 19.5% | 21.6% | 20.7% | 5.7% | 3.6% | 4.0% | 4.7% | 7.4% |
| ROA | 18.0% | 19.4% | 19.0% | 5.5% | 3.4% | 4.0% | 4.5% | 7.1% |
| Net Profit Margin | 35.0% | 34.0% | 36.6% | 36.8% | 20.4% | 22.7% | 26.4% | 36.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Serum Bio-Technology Co. Ltd. A dividends
- Dividend yield
- 1.04%
- Forward dividend
- 0.38 CNY
- Payout ratio
- 66.9%
- Ex-dividend date
- Sep 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 34.6M | 0.32 | 66.9% |
| 2024 | CNY 34.6M | 0.32 | 78.2% |
| 2023 | CNY 81.2M | 0.75 | 209.3% |
| 2022 | CNY 97.4M | 0.90 | 151.7% |
| 2021 | - | - | - |
| 2020 | CNY 106M | 1.30 | 167.0% |
| 2019 | CNY 3.59M | 0.04 | 5.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Serum Bio-Technology Co. Ltd. A
- Insiders 68.87%
- Institutions 0.19%
- Public & others 30.94%
- Shares outstanding 108M
- Free float 44.7M
Shanghai Serum Bio-Technology Co. Ltd. A company profile
- Company name
- Shanghai Serum Bio-Technology Co. Ltd. A
- Ticker
- 688163.SHG
- ISIN
- CNE1000059X8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 330
- Fiscal year end
- December
- Address
- No. 1288, Huaqing Road, Shanghai, China, 201707
- Phone
- 86 21 6076 0783
- Website
- serum-china.com.cn
About Shanghai Serum Bio-Technology Co. Ltd. A
Shanghai Serum Bio-Technology Co., Ltd. engages in research, development, production, operation, and sales of antitoxin and antivenom serum products for biotoxins and biosafety in China. It offers equine anti-tetanus immunoglobulin, antivenom, and anti-rabies serum products. The company also engaged in the collection and sale of animal immune plasma. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co. Ltd. A management
7- Mr. Tiejiong FanGM & Director · born 1985
- Mr. Jin Bao LiuFinancial Director · born 1977
- Mr. Liangjun PengDeputy GM, Core Technical Personnel & Director · born 1961
- Ms. Qiong ChengDeputy GM, Board Secretary & Director · born 1976
- Mr. Zhiping ZhangAssistant to GM & Core Technical Personnel · born 1967
- Mr. Hao ZhangGeneral Manager Assistant · born 1971
- Mr. Binsheng ChenAccounting Supervisor